万古霉素八种群体药动学模型在普通成人中的外部评价
本研究基于文献筛选八种普通成人万古霉素群体药动学模型,利用Charles-Le Moyne医院40例患者252份样本进行外部评价。Goti模型在诊断图和群体预测性能上表现最优,但每患者样本量≤2时预测不准确度超过30%,且需至少两个样本进行贝叶斯预测。
要点
- Goti模型群体预测偏差0.251%、不准确度22.7%,个体预测偏差-4.90%、不准确度12.1%。
- 每患者仅1–2个样本时,Goti模型不准确度超过30%,预测性能不足。
- Goti模型贝叶斯预测下一谷浓度需至少两个样本作为先验。
核心结论
- Goti模型在八种万古霉素群体药动学模型中预测性能最优,适合贝叶斯预测但需至少两个样本。
研究设计与样本
- 研究基于文献综述筛选普通成人万古霉素群体药动学模型,使用Charles-Le Moyne医院40例患者252份样本进行外部评价,采用NONMEM v7.5分析。
主要发现
- Goti模型群体预测偏差0.251%、不准确度22.7%,个体预测偏差-4.90%、不准确度12.1%。
- 每患者限制为1或2个样本时,Goti模型不准确度超过30%。
- Goti模型贝叶斯预测下一谷浓度需至少两个样本作为先验。
关键数值与推荐
- Goti模型最大化AUC24/MIC和谷浓度治疗目标的给药方案为20 mg/kg/次,每日两次。
临床怎么用
- 临床可优先选用Goti模型进行万古霉素TDM,但需确保每患者至少两个样本以支持贝叶斯预测。
局限性
- 外部评价样本量有限(40例患者252份样本),且仅基于单一中心数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Based on the recent guidelines for vancomycin therapeutic drug monitoring (TDM), the area under the curve to minimum inhibitory concentration ratio was to be employed combined with the usage of population pharmacokinetic (popPK) model for dosing adaptation. Yet, deploying these models in a clinical setting requires an external evaluation of their performance. OBJECTIVES: This study aimed to evaluate existing vancomycin popPK models from the literature for the use in TDM within the general patient population in a clinical setting. METHODS: The models under external evaluation were chosen based on a review of literature covering vancomycin popPK models developed in general adult populations. Patients' data were collected from Charles-Le Moyne Hospital (CLMH). The external evaluation was performed with NONMEM® (v7.5). Additional analyses such as evaluating the impact of number of samples on external evaluation, Bayesian forecasting, and a priori dosing regimen simulations were performed on the best performing model. RESULTS: Eight popPK models were evaluated with an independent dataset that included 40 patients and 252 samples. The model developed by Goti and colleagues demonstrated superior performance in diagnostic plots and population predictive performance, with bias and inaccuracy values of 0.251% and 22.7%, respectively, and for individual predictive performance, bias and inaccuracy were -4.90% and 12.1%, respectively. When limiting the independent dataset to one or two samples per patient, the Goti model exhibited inadequate predictive performance for inaccuracy, with values exceeding 30%. Moreover, the Goti model is suitable for Bayesian forecasting with at least two samples as prior for the prediction of the next trough concentration. Furthermore, the vancomycin dosing regimen that would maximize therapeutic targets of area under the curve to minimum inhibitory concentration ratio (AUC24/MIC) and trough concentrations (Ctrough) for the Goti model was 20 mg/kg/dose twice daily. CONCLUSION: Considering the superior predictive performance and potential for Bayesian forecasting in the Goti model, future research aims to test its applicability in clinical settings at CLMH, both in a priori and a posteriori scenario.
引用
- Duong A, El Gamal A, Bilodeau V, et al. Vancomycin: An analysis and evaluation of eight population pharmacokinetic models for clinical application in general adult population. Pharmacotherapy. 2024. PMID: 38803279. doi:10.1002/phar.2941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。